Evidence map›Paper›PMID 28533901›Full record

ArticleClinical and translational allergy2017

Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report.

Ana M Navarro, Julio Delgado, Rosa M Muñoz-Cano, M Teresa Dordal, Antonio Valero, Santiago Quirce, Behalf of the ARD Study Group

Abstract read
In one paragraph

Article in Clinical and translational allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Current opinions for the management of asthma associated with ear, nose and throat comorbidities.European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana M NavarroUGC of Allergy, Hospital El Tomillar , Carretera Alcalá - Dos Hermanas km 6, 41700 Dos Hermanas, Seville Spain.ORCID 0000-0001-7722-6057
Julio DelgadoUGC of Allergy, Hospital Universitario Virgen Macarena, Seville, Spain.
Rosa M Muñoz-CanoAllergy Unit, Pneumology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
M Teresa DordalAllergy Service, Hospital Municipal, Badalona Serveis Assistencials, Badalona, Spain.
Antonio ValeroAllergy Unit, Pneumology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
Santiago QuirceDepartment of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Behalf of the ARD Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe variability of symptoms observed in patients with respiratory allergy often hampers classification based on the criteria proposed in guidelines on rhinitis and asthma.

objectivesWe assessed specific aspects of allergic respiratory disease (ARD) that are not explicitly addressed in the guidelines in order to issue specific recommendations and thus optimize clinical practice.

methodsUsing the Delphi technique, 40 Spanish allergists were surveyed to reach consensus on 71 items related to ARD.

resultsConsensus was achieved for 95.7% of the items. These included the following: the clinical manifestations of ARD are heterogeneous and individual airborne allergens can be related to specific clinical profiles; the optimal approach in patients with ARD is based on the global assessment of rhinoconjunctivitis and asthma; aeroallergens are largely responsible for the clinical features and severity of the disease; and clinical expression is associated with the period of environmental exposure to the allergen. Pharmacological treatment of ARD is often based on the intensity of symptoms recorded during previous allergen exposures and cannot always be administered following a step-up approach, as recommended in clinical practice guidelines. Allergen immunotherapy (AIT) is the only option for overall treatment of respiratory symptoms using an etiological approach. AIT can modify the prognosis of ARD and should therefore be considered a valuable first-line treatment.

conclusionsThe present study highlights gaps in current asthma and rhinitis guidelines and addresses specific aspects of ARD, such as global assessment of both asthma and rhinitis or the specific role of variable allergen exposure in the clinical expression of the disease.

Indexed as

AeroallergensAllergen immunotherapyAllergic asthmaAllergic respiratory diseaseAllergic rhinitisAllergic rhinoconjunctivitisConsensusDelphi methodOne airway

Identifiers

PMID28533901
PMCPMC5437581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.